CD274 and neoplasm: The first of these questions has been the subject of a diverse literature seeking biomarkers of patients likely to respond to therapy from the abundance of PD-L1 expression in the tumour microenvironment to predict responsiveness to ICI targeting the PD-1:PD-L1 axis [17,18], through to evaluations of the immune composition of the tumour microenvironment [19].